- Finasteride inhibits type II 5-alpha-reductase and, at the licensed 1 mg oral dose, reduces serum DHT by roughly 70 percent.
- Oral finasteride 1 mg has been a licensed medicine for male pattern hair loss since the late 1990s.
- RU-58841 is an androgen receptor antagonist first described in the 1980s that does not lower DHT levels.
- RU-58841 has no completed human clinical trial as of October 2026.
- The only controlled RU-58841 evidence is 1990s animal work: Battmann 1994 (PMID 8136306), De Brouwer 1997 (PMID 9415227), Pan and Uno 1998 (PMID 9798729).
- No published study has compared RU-58841 and finasteride head to head.
- Finasteride reduces DHT production throughout the body. RU-58841 blocks DHT at the receptor, only where it is applied.
- Finasteride is a licensed prescription medicine with large clinical trials. RU-58841 has no human clinical trials and is sold as a research chemical.
- The comparison is not between two medicines. It is between a medicine and an unlicensed research compound.
- Nothing here is treatment advice. Everything on this page is for research use only.
The short answer
RU-58841 and finasteride act on DHT-driven hair loss at different points. Finasteride is a licensed medicine that inhibits 5-alpha-reductase and lowers systemic DHT by roughly 70 percent. RU-58841 is an unlicensed research compound that blocks the androgen receptor where it is applied and does not lower DHT. That difference drives the evidence, side effect profile and legal status of each.
Two completely different mechanisms
Dihydrotestosterone, DHT, is an androgen that binds to androgen receptors in the hair follicle and, in genetically susceptible follicles, drives the miniaturisation that shows up as pattern hair loss. There are two clean ways to interfere with that process.
The first is to make less DHT. Finasteride does this by inhibiting the enzyme 5-alpha-reductase, which converts testosterone into DHT. The effect is systemic: DHT falls throughout the body, not just in the scalp. That is why finasteride's effect and its side effects are both body-wide.
The second is to block DHT from binding. RU-58841 is an androgen receptor antagonist. It does not change how much DHT is circulating. It sits on the receptor and competes with DHT for the binding site, so the DHT that is present has less to dock against. Because it is applied topically and designed to act locally, the intended action stays where it is put. That is the entire appeal of the topical antiandrogen approach.
Finasteride: the licensed medicine
Finasteride is a licensed, prescription medicine with decades of use and a large body of randomised controlled trial data behind it. Its mechanism is well characterised, its effect on serum DHT is documented, and its side effect profile, including the sexual side effects that drive a lot of the discussion around it, is formally reported in its prescribing information. Norwood Labs does not sell finasteride, and this is not a commentary on whether anyone should take it. It is simply the standard against which other DHT-related compounds tend to be judged.
RU-58841: the research compound
RU-58841 is a topical androgen receptor antagonist first described in the 1980s. It has never been through human clinical trials, and it is not a licensed medicine anywhere. The direct evidence for it is a handful of old animal studies, including a controlled study in stump-tailed macaques, plus a large body of community reporting. It is sold as a reference material for laboratory research, not as a medicine, and that distinction is the whole point: nothing about its safety or efficacy in humans has been formally established.
Side by side
| Finasteride | RU-58841 | |
|---|---|---|
| Mechanism | 5-alpha-reductase inhibitor | Androgen receptor antagonist |
| Where it acts | Systemic | Local, at the application site |
| Regulatory status | Licensed medicine | Research chemical |
| Human trials | Yes, extensive | None |
| Evidence base | Randomised controlled trials | Old animal studies plus community reports |
| What it does to DHT | Lowers it | Leaves it unchanged, blocks the receptor |
Why they keep getting compared
The comparison usually starts from one place: finasteride's side effect profile. Because it lowers DHT systemically, the effect and any unwanted effects are not confined to the scalp, and a minority of users report persistent sexual side effects that have driven a search for alternatives. RU-58841, in theory, offers the opposite profile: it leaves systemic DHT alone and acts only at the site of application. Whether it actually delivers that theoretical profile in practice is precisely what the missing clinical trials would have answered. They were never run, so the question stays open.
The evidence gap
Finasteride's claims rest on randomised controlled trials with thousands of patients. RU-58841's claims rest on old animal work and uncontrolled community reports. Those are not equivalent categories of evidence, and no honest comparison can treat them as if they were. If the question is which one has proof behind it, the answer is finasteride, without contest. If the question is which one avoids systemic DHT reduction, RU-58841 is the one designed around that property, but the property is assumed rather than clinically demonstrated.
The bottom line
Finasteride is a medicine. RU-58841 is a research chemical. They share a subject matter, not a category. Anyone studying RU-58841 should understand exactly what it is and is not: an unlicensed compound with no human clinical data, sold for laboratory research, not a medicine with an established safety and efficacy profile. Norwood Labs sells RU-58841 and pyrilutamide as reference materials on exactly those terms; our published reports document specific samples.